Product Description
AGT103-T is being developed by American Gene Technologies International for the treatment of HIV infection. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05529342?term=AGT103-T&draw=2&rank=1)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: American Gene Technologies International
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04561258 |
AGT-HC168 | P1 |
Completed |
HIV Infections |
2022-08-15 |
37% |
2023-04-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |